Solomon Moshkevich Sells 24,861 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 24,861 shares of the company’s stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total transaction of $4,101,319.17. Following the sale, the insider now directly owns 140,684 shares of the company’s stock, valued at $23,208,639.48. This represents a 15.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Solomon Moshkevich also recently made the following trade(s):

• On Monday, December 9th, Solomon Moshkevich sold 4,858 shares of Natera stock. The stock was sold at an average price of $166.59, for a total transaction of $809,294.22.
• On Monday, October 28th, Solomon Moshkevich sold 1,196 shares of Natera stock. The shares were sold at an average price of $118.21, for a total value of $141,379.16.

Natera Price Performance

Shares of Natera stock opened at $167.61 on Friday. Natera, Inc. has a twelve month low of $62.96 and a twelve month high of $183.00. The firm has a market cap of $22.13 billion, a P/E ratio of -95.23 and a beta of 1.65. The firm’s 50-day simple moving average is $166.20 and its 200-day simple moving average is $136.25. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm had revenue of $439.80 million during the quarter, compared to analyst estimates of $361.43 million. During the same period in the prior year, the company posted ($0.95) earnings per share. The business’s revenue for the quarter was up 63.9% compared to the same quarter last year. As a group, research analysts expect that Natera, Inc. will post -1.56 EPS for the current fiscal year.

Hedge Funds Weigh In On Natera

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NTRA. Wellington Management Group LLP raised its stake in shares of Natera by 205.4% in the third quarter. Wellington Management Group LLP now owns 2,800,263 shares of the medical research company’s stock valued at $355,493,000 after acquiring an additional 1,883,481 shares during the last quarter. AQR Capital Management LLC raised its position in Natera by 257.6% in the 2nd quarter. AQR Capital Management LLC now owns 651,523 shares of the medical research company’s stock valued at $70,553,000 after purchasing an additional 469,327 shares during the last quarter. PointState Capital LP boosted its stake in Natera by 112.0% in the third quarter. PointState Capital LP now owns 782,538 shares of the medical research company’s stock worth $99,343,000 after purchasing an additional 413,468 shares in the last quarter. Franklin Resources Inc. grew its holdings in shares of Natera by 42.6% during the third quarter. Franklin Resources Inc. now owns 1,099,335 shares of the medical research company’s stock worth $144,958,000 after purchasing an additional 328,375 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. increased its stake in shares of Natera by 36.1% in the second quarter. D. E. Shaw & Co. Inc. now owns 1,145,362 shares of the medical research company’s stock valued at $124,031,000 after buying an additional 303,905 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

NTRA has been the topic of a number of research analyst reports. JPMorgan Chase & Co. boosted their price objective on shares of Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, December 13th. Sanford C. Bernstein upped their price target on shares of Natera from $160.00 to $200.00 and gave the stock an “outperform” rating in a research note on Friday, January 10th. Leerink Partners upped their target price on Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. Canaccord Genuity Group upped their price objective on shares of Natera from $165.00 to $180.00 and gave the stock a “buy” rating in a report on Friday, January 3rd. Finally, TD Cowen boosted their target price on shares of Natera from $155.00 to $175.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $162.94.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.